Erasca Faces Securities Class Action After Stock Declines 48%
Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after its stock dropped 48% on news of patent infringement allegations and drug safety concerns.
Biotechnology company Erasca, Inc. (NASDAQ: ERAS) is facing a securities class action lawsuit. The suit was filed following a significant decline in the company's stock price, which fell 48% on July 7, 2026, after the market received new information.
The stock's drop was attributed to two key developments: competitor Revolution Medicines (RevMed) accused Erasca of patent infringement related to Erasca's pan-RAS molecular glue targeting solid tumors. Additionally, concerns have been raised regarding the safety profile of Erasca's drug development pipeline.
Erasca, headquartered in San Francisco, has stated that it is reviewing the allegations and intends to respond accordingly. The company has indicated that the patent dispute concerns core technology central to its development efforts.
Investors reacted negatively to the news, leading to the substantial stock value decrease and the subsequent class action lawsuit. The outcome of the legal proceedings and their potential impact on Erasca's future development plans remain uncertain.